Microbix Develops Team to Help Boost Flu Vaccine Production
ePT--the Electronic Newsletter of Pharmaceutical Technology
Microbix Biosystems has established a team of experts to help manufacturers boost their production of influenza vaccine.
Toronto, ON, Canada (Aug. 13)-Microbix Biosystems has established a team of experts to help manufacturers boost their production of influenza vaccine. The “Special Workgroup for Applied Technology Transfer” or “SWATT” group, working with the company’s “VirusMax” technology, spends several weeks at each facility to help implement the technology and train personnel.
The VirusMax technology is designed to increase the virus yield from eggs by effectively recovering the virus. “Our technology can be installed very quickly, and with limited capital costs into existing manufacturing processes,” said William J. Gastle, CEO of Microbix, in a prepared statement. According to the company, the technology has been shown to double vaccine production.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
